The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Beam Therapeutics Inc.

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric ...

Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia

WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno ...

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Akero Therapeutics Inc.

Spanish biotech SpliceBio has signed a licensing agreement with Spark Therapeutics to utilise the latter’s proprietary protein splicing platform and develop a gene therapy for an undisclosed ...

Spark Therapeutics partners with SpliceBio for gene therapy

One of the tracks of SLAS EU 2023 is Shaping the Future of Therapeutics. How do you believe 3D Imaging Mass Cytometry is shaping the future of therapeutics? At the moment, I think 3D imaging mass ...

Shaping the Future of Therapeutics with 3D Imaging Mass Cytometry

Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Repare Therapeutics (RPTX – Research Report) today and set a price target of $25.00. The company’s shares closed last Friday ...

Piper Sandler Keeps Their Buy Rating on Repare Therapeutics (RPTX)

SkyGem Acquisition has launched a mandatory offer to buy the remaining shares of Allergy Therapeutics after increasing its shareholding past 30%, in a deal that values the company at 47.9 million ...

Allergy Therapeutics Gets GBP48 Million Takeover Offer From SkyGem

Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by ...

Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil

Glenmark Pharmaceuticals Ltd on Thursday said its wholly-owned arm Ichnos Sciences has signed an exclusive worldwide licensing agreement with Astria Therapeutics for its OX40 antagonist monoclonal ...

Stories, News & Mentions about ATRIVATHERAPEUTICS

Atrivatherapeutics's News & Mentions